Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
Adult
Biomarkers
/ analysis
C-Reactive Protein
/ analysis
Crohn Disease
/ blood
Feces
/ chemistry
Female
Gastrointestinal Agents
/ pharmacology
Humans
Leukocyte L1 Antigen Complex
/ analysis
Male
Middle Aged
Predictive Value of Tests
Prognosis
Recurrence
Remission Induction
Severity of Illness Index
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Young Adult
Anti-tumor necrosis factor
Biomarkers
C-reactive protein
Crohn’s disease
Crohn’s disease activity index
Faecal calprotectin
Tight control
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 May 2019
21 May 2019
Historique:
received:
07
03
2019
revised:
16
04
2019
accepted:
19
04
2019
entrez:
1
6
2019
pubmed:
1
6
2019
medline:
4
12
2019
Statut:
ppublish
Résumé
The individual performances and the complementarity of Crohn's disease (CD) activity index (CDAI), C-reactive protein (CRP) and faecal calprotectin (Fcal) to monitor patients with CD remain poorly investigated in the era of "tight control" and "treat to target" strategies. To assess CDAI, CRP and Fcal variation, alone or combined, after 12 wk (W12) of anti-tumor necrosis factor (TNF) therapy to predict corticosteroids-free remission (CFREM = CDAI < 150, CRP < 2.9 mg/L and Fcal < 250 μg/g with no therapeutic intensification and no surgery) at W52. CD adult patients needing anti-TNF therapy with CDAI > 150 and either CRP > 2.9 mg/L or Fcal > 250 μg/g were prospectively enrolled. Among the 40 included patients, 13 patients (32.5%) achieved CFREM at W52. In univariable analysis, CDAI < 150 at W12 ( The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD.
Sections du résumé
BACKGROUND
BACKGROUND
The individual performances and the complementarity of Crohn's disease (CD) activity index (CDAI), C-reactive protein (CRP) and faecal calprotectin (Fcal) to monitor patients with CD remain poorly investigated in the era of "tight control" and "treat to target" strategies.
AIM
OBJECTIVE
To assess CDAI, CRP and Fcal variation, alone or combined, after 12 wk (W12) of anti-tumor necrosis factor (TNF) therapy to predict corticosteroids-free remission (CFREM = CDAI < 150, CRP < 2.9 mg/L and Fcal < 250 μg/g with no therapeutic intensification and no surgery) at W52.
METHODS
METHODS
CD adult patients needing anti-TNF therapy with CDAI > 150 and either CRP > 2.9 mg/L or Fcal > 250 μg/g were prospectively enrolled.
RESULTS
RESULTS
Among the 40 included patients, 13 patients (32.5%) achieved CFREM at W52. In univariable analysis, CDAI < 150 at W12 (
CONCLUSION
CONCLUSIONS
The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD.
Identifiants
pubmed: 31148906
doi: 10.3748/wjg.v25.i19.2354
pmc: PMC6529885
doi:
Substances chimiques
Biomarkers
0
Gastrointestinal Agents
0
Leukocyte L1 Antigen Complex
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2364Déclaration de conflit d'intérêts
Conflict-of-interest statement: Buisson A declares lecture fees for MSD, Abbvie, Ferring, Takeda, Vifor Pharma, Hospira and consulting fees for Abbvie, Takeda and Hospira. Bouguen G received lecture fees from Abbvie, Ferring, MSD, Takeda and Pfizer and consulting fees from Takeda and Janssen. The other authors declare no conflict of interest related to this work.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Inflamm Bowel Dis. 2011 Jun;17(6):1415-22
pubmed: 21560202
Gut. 2012 Feb;61(2):241-7
pubmed: 21646246
Aliment Pharmacol Ther. 2011 Oct;34(8):911-22
pubmed: 21883326
Inflamm Bowel Dis. 2012 Nov;18(11):2011-7
pubmed: 22223566
Aliment Pharmacol Ther. 2012 Mar;35(5):568-76
pubmed: 22251435
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24
pubmed: 22344983
Dig Liver Dis. 2013 Jul;45(7):569-72
pubmed: 23298761
Gut. 2014 Jan;63(1):88-95
pubmed: 23974954
United European Gastroenterol J. 2014 Feb;2(1):30-7
pubmed: 24918006
Dig Liver Dis. 2014 Nov;46(11):974-9
pubmed: 25096964
Gastroenterology. 2015 Jan;148(1):52-63.e3
pubmed: 25241327
Inflamm Bowel Dis. 2015 Feb;21(2):331-6
pubmed: 25625487
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
J Crohns Colitis. 2015 Dec;9(12):1113-9
pubmed: 26351383
Inflamm Bowel Dis. 2017 Aug;23(8):1425-1433
pubmed: 28570431
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949